Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.

Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.

Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.

Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Abstract: The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

Abstract: A system and method for analyzing volatile organic compounds (VOCs) adsorbed on an adsorbent membrane, by low-temperature plasma and mass spectrometry (LTP-MS). The system includes a receptacle for receiving the adsorbent membrane, a low-temperature plasma ionizer configured to emit a plasma stream in a plasma emission direction, thereby ionizing the VOCs adsorbed by the membrane and forming a VOC-laden ionized gas, and a mass spectrometer for analyzing the ionized VOCs.

Abstract: A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from

Abstract: The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases.

Abstract: Peptides endowed with an anti-inflammatory, anti-angiogenic and/or antimicrobial activity, a medicament or a pharmaceutical composition including such peptides, and the use thereof in the prevention or treatment of inflammatory diseases, and more particularly inflammatory diseases due to or associated with microbial infections, or in the prevention or treatment of angiogenesis-related diseases.

Abstract: An insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment, and in particular for preventing or treating the loss of vision induced by retinal detachment. Also, a composition including the insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment and a device including the composition.

Abstract: The sensory substitution system includes a portable matrix of exciters that can be worn by a user in such a way that the exciters are placed against the skin of a user, as well as a control circuit for the exciters of the matrix. An asynchronous signal source provides the control circuit with an asynchronous signal representative of visual information organised according to a matrix of pixels. This asynchronous signal includes, for each pixel, successive events associated in an asynchronous manner with the pixel.

Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.

Abstract: A method for predicting the return to functional autonomy in a subject suffering from an acute event, including the steps of i) determining neopterin level in a biological sample obtained from the subject; ii) comparing the level with its predetermined reference neopterin level and iii) predicting that the subject will have a long time to return to functional autonomy when the level of neopterin is higher than its predetermined reference neopterin level or predicting that the subject will have a short time to return to functional autonomy when the level of neopterin is lower than its predetermined reference neopterin level.

Abstract: In the field of immunotherapy, a chimeric antigen receptor (CAR) specific for-human CD45RC. Also, the immune cells expressing this CAR and the use thereof as a medicament. In particular, the use of this CAR for preventing or treating CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, lymphoma or cancer), or graft-versus-host disease (GVHD).

Abstract: A system for automatic evaluation of cognition and consciousness of a subject, the system including a micro-controller, a digital-to-analog converter and at least one sensory stimulation element, wherein the system is configured to receive as input an information concerning a stimulation paradigm and to generate as output a sensory stimulation according to the stimulation paradigm and transmit at least one synchronization signal determined by the stimulation paradigm to a device for the acquisition of a physiological signal so as to synchronize the system for stimulation with the device for the acquisition of a physiological signal during an acquisition.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

Abstract: The present invention aims at improving the Doppler imaging of a biological sample comprising blood. For this, it is proposed a method for imaging a biological sample (10), the sample (10) comprising blood (14) comprising diffusors and solid tissue (16), the method comprising obtaining observation, each observation being characterized by a different point spread function associating a signal to each location of the region of interest, the signal comprising a first contribution representative of the diffusors of blood vessels within the location, a second contribution representative of the tissue diffusors and a third contribution representative of blood signal associated to blood diffusors outside of the location, and estimating, for each location, the blood flow by using a statistical analysis.